➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Merck
Colorcon
Mallinckrodt

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for GKT137831

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GKT137831?

GKT137831 is an investigational drug.

There have been 5 clinical trials for GKT137831. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2019.

The most common disease conditions in clinical trials are Fibrosis, Liver Cirrhosis, Biliary, and Cholangitis. The leading clinical trial sponsors are Genkyotex SA, University of Alabama at Birmingham, and York Bioanalytical Solution.

There are seven US patents protecting this investigational drug and sixty-two international patents.

Recent Clinical Trials for GKT137831
TitleSponsorPhase
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female SubjectsGenkyotex SAPhase 1
GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisUniversity of Alabama at BirminghamPhase 2
Bioequivalence StudyEurofins OptimedPhase 1

See all GKT137831 clinical trials

Clinical Trial Summary for GKT137831

Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831

See all GKT137831 clinical trials

US Patents for GKT137831

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GKT137831   Start Trial Skin enhancing compositions and methods Sytheon Limited (Boonton, NJ)   Start Trial
GKT137831   Start Trial Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (Plan-les-Ouates, CH)   Start Trial
GKT137831   Start Trial Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 Eastern Virginia Medical School (Norfolk, VA)   Start Trial
GKT137831   Start Trial Orvepitant for chronic cough therapy NeRRe Therapeutics Limited (Herts, GB)   Start Trial
GKT137831   Start Trial Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents NeRRe Therapeutics Limited (Herts, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GKT137831

Drugname Country Document Number Estimated Expiration Related US Patent
GKT137831 European Patent Office EP3532019 2036-10-31   Start Trial
GKT137831 South Korea KR20190082254 2036-10-31   Start Trial
GKT137831 World Intellectual Property Organization (WIPO) WO2018081779 2036-10-31   Start Trial
GKT137831 Australia AU2009298008 2028-09-23   Start Trial
GKT137831 Brazil BRPI0919330 2028-09-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Merck
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.